Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.

Ball S, Li C, Li PK, Lin J.

PLoS One. 2011 Apr 19;6(4):e18820. doi: 10.1371/journal.pone.0018820.

2.

A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.

Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, Lin J.

Neoplasia. 2010 Jan;12(1):39-50.

3.

A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.

Lin L, Benson DM Jr, DeAngelis S, Bakan CE, Li PK, Li C, Lin J.

Int J Cancer. 2012 Mar 15;130(6):1459-69. doi: 10.1002/ijc.26152. Epub 2011 Aug 26.

4.

Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.

Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJ.

PLoS One. 2012;7(4):e35513. doi: 10.1371/journal.pone.0035513. Epub 2012 Apr 17.

5.

Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.

Wei CC, Ball S, Lin L, Liu A, Fuchs JR, Li PK, Li C, Lin J.

Int J Oncol. 2011 Jan;38(1):279-85.

PMID:
21109950
6.

LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.

Zuo M, Li C, Lin J, Javle M.

Oncotarget. 2015 May 10;6(13):10940-9.

7.

Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.

Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, Termuhlen A, Gross T, Lin J.

Invest New Drugs. 2012 Jun;30(3):916-26. doi: 10.1007/s10637-011-9645-1. Epub 2011 Feb 22.

PMID:
21340507
8.

Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.

Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA.

BMC Vet Res. 2012 Dec 17;8:244. doi: 10.1186/1746-6148-8-244.

9.

Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells.

Lin L, Hutzen B, Lee HF, Peng Z, Wang W, Zhao C, Lin HJ, Sun D, Li PK, Li C, Korkaya H, Wicha MS, Lin J.

PLoS One. 2013 Dec 23;8(12):e82821. doi: 10.1371/journal.pone.0082821. eCollection 2013.

10.

Characterization of STAT3 activation and expression in canine and human osteosarcoma.

Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA.

BMC Cancer. 2009 Mar 10;9:81. doi: 10.1186/1471-2407-9-81.

11.

Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.

Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, Schroeder A, Jensen M, Jove R.

Mol Cancer Ther. 2010 Apr;9(4):953-62. doi: 10.1158/1535-7163.MCT-09-0947. Epub 2010 Apr 6.

12.

A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells.

Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C, Houghton PJ, Lin J.

J Biol Chem. 2015 Feb 6;290(6):3418-29. doi: 10.1074/jbc.M114.616748. Epub 2014 Oct 13.

13.

Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y.

Int J Oncol. 2013 Jul;43(1):219-27. doi: 10.3892/ijo.2013.1916. Epub 2013 Apr 23.

PMID:
23612755
14.

Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.

Senft C, Priester M, Polacin M, Schröder K, Seifert V, Kögel D, Weissenberger J.

J Neurooncol. 2011 Feb;101(3):393-403. doi: 10.1007/s11060-010-0273-y. Epub 2010 Jun 30.

PMID:
20589525
15.
16.

Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells.

Liu Y, Li PK, Li C, Lin J.

J Biol Chem. 2010 Aug 27;285(35):27429-39. doi: 10.1074/jbc.M110.142752. Epub 2010 Jun 18.

17.

Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.

Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H.

Mol Cancer Res. 2010 Jan;8(1):35-45. doi: 10.1158/1541-7786.MCR-09-0220. Epub 2010 Jan 6.

18.

Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma.

Brown ME, Bear MD, Rosol TJ, Premanandan C, Kisseberth WC, London CA.

BMC Vet Res. 2015 Aug 14;11:206. doi: 10.1186/s12917-015-0505-7.

19.

STAT3 is necessary for proliferation and survival in colon cancer-initiating cells.

Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J.

Cancer Res. 2011 Dec 1;71(23):7226-37. doi: 10.1158/0008-5472.CAN-10-4660. Epub 2011 Sep 7.

20.

A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.

Kim BH, Yin CH, Guo Q, Bach EA, Lee H, Sandoval C, Jayabose S, Ulaczyk-Lesanko A, Hall DG, Baeg GH.

Mol Cancer Ther. 2008 Sep;7(9):2672-80. doi: 10.1158/1535-7163.MCT-08-0309.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk